Abstract
Target identification aims at identifying biomolecules whose function should be therapeutically modified to cure the considered pathology. An algorithm for in silico target identification using boolean network attractors is proposed. It assumes that boolean network attractors correspond to the phenotypes produced by the modeled biological network. It identifies target combinations which allow disturbed biological networks to avoid attractors responsible for pathological phenotypes. The algorithm is tested on a boolean model of the mammalian cell cycle where retinoblastoma protein is inactivated, as seen in diseases such as cancer. It returns target combinations able to remove attractors responsible for pathological phenotypes. Results show that the algorithm succeeds in performing the proposed in silico target identification. However, as with any in silico evidence, there is a bridge to cross between theory and practice. Nevertheless, it is expected that the algorithm is of interest for target identification. 
Introduction
Drug discovery, as its name indicates, aims at discovering new effective drugs against diseases. This process can be segmented into three steps: i) disease model provision, where experimental models are developed, ii) target identification, where new therapeutic targets are proposed and iii) target validation, where the proposed therapeutic targets are assessed. The present work focuses on the second step of drug discovery: target identification [1, 2] . Given an organism suffering from a disease, it aims at finding where to act among its multitude of biomolecules in order to alleviate, or ultimately to cure, the physiological consequences of the disease. These biomolecules on which perturbations should be applied are called targets and are targeted by drugs [3] . This raises two questions: which target should be therapeutically perturbed and what type of perturbation should be applied. Broadly, the functional perturbation of a target by a drug can be either activating or inactivating, regardless the way the drug achieves it.
One solution is to test all, or at least a large number of, biomolecules for activation or inactivation. Knowing that targeting several biomolecules is potentially more effective [4] , the number of possibilities is consequently huge. This rather brute force screening can be refined with knowledge about the disease pathophysiology by identifying potential targets based on the role they play in it [5] . Even with this knowledge, experimentally assessing in vitro or in vivo the selected potential targets is far from being straightforward. Indeed, such experiments are costly in time and resources and exhibit a high risk of failure [6] . Fortunately, in silico experiments appear as valuable tools in improving the efficiency of therapeutic researches [7] since they are less costly in time and resources than the traditional in vitro and in vivo ones. However, the stumbling block of in silico experiments is that they are built from the available knowledge about the pathophysiology of interest: not all is known about everything.
Nevertheless, an impressive and ever increasing amount of biological knowledge is already available in scientific literature, databases and knowledge bases such as, to name a few, DrugBank [8] , KEGG [9] , PharmGKB [10] , Reactome [11] and TTD [12] . In addition to the complexity of integrating an increasing body of knowledge comes the inherent complexity of biological systems themselves [13] : this is where computational tools can help [14] . The interplay between traditional and computational biology is synergistic rather than competing [15] . Since in vitro and in vivo experiments produce rather factual results, they are relatively trustworthy sources of knowledge. Once these factual pieces of knowledge are obtained, computational tools can help to integrate them and infer new ones. This computationally obtained knowledge can be subsequently used to direct further in vitro or in vivo experiments, hence mutually potentiating the whole.
The goal of the present work is to propose a computational methodology implemented in an algorithm for target identification using boolean network attractors. It assumes that boolean network attractors correspond to the phenotypes produced by the modeled biological network, an assumption successfully applied in several works [16] [17] [18] [19] [20] [21] to cite a few. Assuming that a phenotype is an observable and hence a relatively stable state of a biological system and assuming that the state of a biological system is due to the dynamic of the underlying biological network, a phenotype is likely to correspond to an attractor. This assumption can be stated for any dynamical model but, in the present work, only boolean networks are considered. Reasons are that, in their most basic form, boolean networks do not require parameter values [22] and that parameter values are not straightforward to obtain in biology, particularly at the subcellular scale, the scale where drugs interact with their targets. Since synchronous boolean networks are easier to compute than asynchronous ones [23] , only synchronous boolean networks are considered. This does not exclude the possibility, at a later stage, to extend the algorithm for both synchronous and asynchronous updating schemes.
For a biological network involved in a disease pathophysiology, two possible variants are considered: the physiological variant, bore by healthy organisms, which produces physiological phenotypes, and the pathological variant, bore by ill organisms, which produces pathological phenotypes or which fails to produce physiological ones. A physiological phenotype does not impair life quantity/ quality while a pathological phenotype does. It should be noted that the loss of a physiological phenotype is also a pathological condition. The physiological and pathological variants differ in that the second one results from the occurrence of some modifications known to be responsible for disorders. With a pathological variant, there are two non exclusives pathological scenarios: pathological phenotypes are gained or physiological phenotypes are lost.
The primary goal of the algorithm is to identify, in the pathological variant, target combinations together with the perturbations to apply on them, here called bullets, which make it unable at producing pathological phenotypes. The secondary goal is to classify the obtained bullets according to their ability at making the pathological variant producing the lost physiological phenotypes, if any.
Methods
This section briefly introduces some basic principles, namely biological networks [24, 25] and boolean networks [26] , states some particular definitions and then describes the proposed algorithm. An example network to illustrate it together with its implementation are also described.
Basic principles

Biological networks
A network can be seen as a graph G = (V, E) where V = {v 1 , . . . , v n } is the set of size n containing exactly all the nodes v i of the network and where
2 is the set of size m containing exactly all the edges (v i , v j ) of the network [27, 28] . In practice, nodes represent things and edges represent binary relations R ⊆ V 2 involving these things: v i R v j . For example, in gene regulatory networks, nodes represent gene products and edges represent gene expression modulations [29] .
Boolean networks
A boolean network is a network where nodes are boolean variables x i and where edges (x i , x j ) represent the binary is input of relation: x i is input of x j . Each
The variables which are not input of x i have no direct influence on it. In the case where b i = 0, x i is a parameter, or an input, and does not depend on other variables. At each iteration k ∈ [[k 0 , k end ]] of the simulation, the value x i (k) ∈ {0, 1} of each x i is updated to the value x i (k + 1) thanks to a boolean function f i and to the values x i,1 (k), . . . , x i,bi (k) of its inputs: 5 end for which can be written in a more concise form:
n of x at k belongs to the state space S = {0, 1}
n which is the set of size 2 n containing exactly all the possible states. If the values of all the x i are updated simultaneously at each k then the network is synchronous, otherwise it is asynchronous. With synchronous boolean networks, at each k, x(k) has a unique possible successor x(k + 1): synchronous boolean networks are deterministic.
In the particular case where k = k 0 , x(k 0 ) = x 0 is the initial state and, in deterministic dynamical systems, determines entirely the trajectory w = (x(k 0 ), . . . , x(k end )). w is a sequence of length k end 1 and results from the iterative computation of x(k) from k 0 to k end . This iterative computation can be seen as the discretization of a time interval: boolean networks are discrete dynamical systems as they simulate, discretely, the time course of the state vector.
The set A = {a 1 , . . . , a p } of size p containing exactly all the attractors a i is the attractor set. Due to the determinism of synchronous boolean networks, all the attractors are cycles. A cycle is a sequence (x 1 , . . . , x q ) of length q such that ∀j ∈ [ [1, q] ], x j+1 = f (x j ) and x q+1 = x 1 : once the system reaches a state x j belonging to a cycle, it successively visits its states x j+1 , . . . , x q , x 1 , . . . , x j for infinity. In the particular case where q = 1, the cycle is a point attractor.
The set B i ⊆ S containing exactly all the x ∈ S from which a i can be reached is its basin of attraction. With deterministic dynamical systems, the family of sets (B 1 , . . . , B p ) constitutes a partition of S.
Definitions
Some particular concepts used in the present work should be formally defined.
• physiological phenotype: a phenotype which does not impair the quantity/ quality of life of the organism which exhibits it.
• pathological phenotype: a phenotype which impairs the quantity/quality of life of the organism which exhibits it.
• variant (of a biological network): a biological network derived from the original one where some modifications occurred in its structure.
• physiological variant : a variant which produces only physiological phenotypes.
• pathological variant : a variant which produces at least one pathological phenotype.
• physiological attractor set : the attractor set A physio of the physiological variant.
• pathological attractor set : the attractor set A patho of the pathological variant.
• physiological boolean transition function: the boolean transition function f physio of the physiological variant.
• pathological boolean transition function: the boolean transition function f patho of the pathological variant.
• run: an iterative computation of x(k) starting from x 0 until an a i is reached. It returns w = (x(k 0 ), . . . , x(k end )) where k end depends on when a i is reached and hence on x 0 .
• physiological attractor : an a i such that a i ∈ A physio .
• pathological attractor : an a i such that a i / ∈ A physio .
• modality: the functional perturbation moda i applied on an entity v j ∈ V of the network, either activating (moda i = 1) or inactivating (moda i = 0): at each k, moda i overwrites f j (x(k)) and hence x j (k + 1) = moda i .
• target : an entity targ i ∈ V of the network on which a moda i is applied.
• bullet : a couple (c targ , c moda ) where c targ = (targ 1 , . . . , targ r ) is a combination without repetition of targ i and where c moda = (moda 1 , . . . , moda r ) is an arrangement with repetition of moda i , r ∈ [ [1, n] ] being the number of targets in the bullet. moda i is intended to be applied on targ i .
• therapeutic bullet : a bullet which makes A patho ⊆ A physio .
• silver bullet : a therapeutic bullet which makes A patho A physio .
• golden bullet : a therapeutic bullet which makes A patho = A physio . The assumed link between phenotypes and attractors is the reason why attractors are qualified as either physiological or pathological according to the phenotype they produce. This is also the reason why, in the present work, target identification aims at manipulating the attractor set of the pathological variant.
Steps of the algorithm
The algorithm has two goals: i) finding therapeutic bullets and ii) classifying them as either golden or silver. A therapeutic bullet makes the pathological variant unable at reaching pathological attractors, that is A patho ⊆ A physio . If such a bullet is applied on a pathological variant, the organism bearing it no longer exhibits the associated pathological phenotypes. However, a therapeutic bullet does not necessarily preserve/restore the physiological attractors. If a therapeutic bullet preserves/restores the physiological attractors, namely if A patho = A physio , then it is a golden one but if A patho A physio then it is a silver one.
Given a physiological and a pathological variant, that is f physio and f patho , the algorithm follows five steps:
1. with f physio it computes the control attractor set A physio 2. it generates bullets and, for each of them, it performs the three following steps 3. with f patho plus the bullet, it computes the variant attractor set A patho 4. it assesses the therapeutic potential of the bullet by comparing A physio and A patho to detect pathological attractors 5. if the bullet is a therapeutic one then it classifies it as either golden or silver by comparing A physio and A patho for equality which can be written:
The algorithm is described step by step but can be found in one block in annexes page 16.
Step 1: computing A physio
First of all, A physio has to be computed since it is the control and, as such, determines what is pathological and what is not. To do so, runs are performed with f physio and the reached a i are stored in A physio . However, x 0 ∈ S and size(S) increases exponentially with n. Even for reasonable n, size(S) explodes: more than one million possible x 0 for n = 20. One solution ensuring that all the a i are reached is to start a run from each of the possible x 0 , that is from each of the x ∈ S. Practically, this is unfeasible for an arbitrary value of n since the required computational resources can be too demanding. For example, assuming that a run requires one millisecond and that n = 50, performing a run from each of the 2 50 x ∈ S requires nearly 36 thousand years. Given that with deterministic dynamical systems (B 1 , . . . , B p ) is a partition of S, a solution is to select a subset D ⊆ S of a reasonable size containing the x 0 to start from. In the present work, D is selected randomly along a uniform distribution. The stumbling block of this solution is that it does not ensure that at least one x 0 per B i is selected and then does not ensure that all the a i are reached. This stumbling block holds only if size(D) < size(S).
Again given that synchronous boolean networks are deterministic, if a run visits a state already visited in a previous run then its destination, that is the reached attractor, is already found. If so, the run can be stopped and the algorithm can jump to the next one. To implement this, the previous trajectories are stored in a set H, the history, and at each k the algorithm checks if ∃w ∈ H : x(k) ∈ w. If this check is positive then the algorithm jumps to the next run.
Since with deterministic dynamical systems attractors are cycles, the algorithm checks at each k if x(k + 1) is an already visited state of the current run, namely if ∃k
). This step can be written:
while true do The purpose of the present work is not to propose an algorithm for finding boolean network attractors since more sophisticated algorithms for such tasks are already published [30, 31] . The purpose is to exploit boolean network attractors for target identification and, as a consequence, requires these attractors to be found.
Step 2: generating bullets
Bullets are candidate perturbations to apply on the pathological variant to make it unable at reaching pathological attractors and hence unable at producing pathological phenotypes. Generating a bullet is to choose some targ i ∈ V and to choose for each of them a moda i ∈ {0, 1}. In the present work, there is no time sequencing in target engagement nor in modality application. This means that, given a bullet and during a given run, all the targ i are engaged simultaneously and constantly and that the moda i do not change. As a consequence, for a given bullet, choosing more than once the same targ i is senseless while it is possible to choose the same moda i for more than one targ i . Therefore, a bullet is a combination c targ without repetition of targ i together with an arrangement c moda with repetition of moda i .
If bullets containing r targets have to be generated then there are n!/(r! · (n − r)!) possible c targ and, for each of them, there are 2 r possible c moda . This raises the same difficulty than with state space size explosion since there are (n! · 2 r )/(r! · (n − r)!) possible bullets. For example, assuming that n = 50 and that r = 3, there are more than 150 thousand possible bullets. Knowing that the algorithm, as explained below, computes one attractor set per bullet, the computation time becomes practically unfeasible. To overcome this barrier, the algorithm asks for r as an interval [[r min , r max ]], asks for a maximum number max targ of c targ to generate and asks for a maximum number max moda of c moda to test for each c targ . Then, the algorithm generates a set C targ of c targ with size(C targ ) ≤ max targ by randomly selecting, along a uniform distribution and without repetition, entities in the network. In the same way, the algorithm generates a set C moda of c moda with size(C moda ) ≤ max moda by randomly choosing, along a uniform distribution and with repetition, modalities as either activating (= 1) or inactivating (= 0).
The result is the bullets: per r ∈ [[r min , r max ]], a C targ together with a C moda . As with state space size explosion, the stumbling block of this method is that it does not ensure that all the possible c targ together with all the possible c moda are tested. This stumbling block holds only if max targ < n!/(r! · (n − r)!) or max moda < 2 r . This step can be written: do steps 3 to 5 19 end for 20 return golden_set, silver_set Line 2 catches the mistake r > n. Lines 3 and 4 create sets in which therapeutic bullets found in step 4 are classified as either golden or silver in step 5. Lines 6 and 7 catch the mistake where max targ or max moda is greater than its maximum, which depends on r, hence the creation of max r targ and max r moda to preserve the initially supplied value. Lines 11 and 15 ensure that only new c targ and c moda are generated.
Step 3: computing A patho
Having the control attractor set A physio and a bullet (c targ , c moda ) ∈ C targ × C moda , the algorithm computes the variant attractor set A patho under the effect of the bullet by almost the same way A physio is computed in step 1. However, in this step, f patho is used instead of f physio and the bullet is applied: at each k,
In order to apply all the generated bullets, the algorithm uses two nested f or loops. For each c targ ∈ C targ it uses successively all the c moda ∈ C moda . For each (c targ , c moda ), the algorithm computes the corresponding A patho and does steps 4 and 5.
This step can be written:
while true do 
Step 4: identifying therapeutic bullets
To identify therapeutic bullets among the generated ones, for each (c targ , c moda ) tested in step 3 and once the corresponding A patho is obtained, the algorithm compares it with A physio to check if A patho ⊆ A physio . This check ensures that, under the effect of the bullet, all the pathological attractors are removed and that if new attractors appear then they are physiological ones. If this check is positive then the bullet is therapeutic and the algorithm pursues with step 5.
Step 5: assessing therapeutic bullets Therapeutic bullets are qualified as either golden or silver according to their ability at making the pathological variant reaching the physiological attractors. All therapeutic bullets, being golden or silver, remove pathological attractors without creating new ones, that is A patho ⊆ A physio . However, this does not imply that therapeutic bullets preserve/restore physiological attractors. A golden bullet preserves/restores physiological attractors: A patho = A physio while a silver bullet does not: A patho A physio .
In this setting, golden bullets are perfect therapies while silver bullets are not. However, since precious things are rare and since gold is rarer than silver, finding a golden bullet is less likely than finding a silver one. Indeed, given that more constraints are required for a therapeutic bullet to be a golden one, it is more likely that the found therapeutic bullets are silver ones.
Practically, again in the present setting, an organism bearing a pathological variant treated with a therapeutic bullet no longer exhibits the associated pathological phenotypes. Moreover, if the therapeutic bullet is a golden one, the organism exhibits the same phenotypes than its healthy counterpart. However, if the therapeutic bullet is a silver one, the organism fails to exhibit at least one physiological phenotype. With a silver bullet this is a matter of choice: what is less detrimental between a silver bullet and no therapeutic bullet at all.
Example network
The algorithm is used on a published boolean model of the mammalian cell cycle [18] to test and illustrate it. This model is chosen for several reasons: i) a synchronous updating scheme is performed: to date, the algorithm focuses on synchronous boolean networks, ii) a mammalian biological system is modeled: the closer to human physiology the model is the better it illustrates the intended applications, iii) the cell cycle is a at the heart of cancer: this gives relevancy to the example network, iv) the network comprises ten nodes: easily computable in face of its state space and v) attractors are already computed: useful to validate the algorithm in finding them.
Below are the boolean functions of the example network where, for the sake of readability, x i stands for x i (k) and x i+ stands for x i (k + 1).
Having the example network, two variants of it are needed: the physiological one and the pathological one. The physiological variant is the network as is while the pathological variant is the network plus a constitutive activation/inactivation of at least one of its entities. For simplicity, and given the relatively small number of entities, only one is chosen: retinoblastoma protein Rb, for which a constitutive inactivation is applied. To implement this, the corresponding f i becomes Rb + = 0 in f patho . Rb is chosen because its inactivation occurs in many cancers [32] and, as a consequence, a network bearing a constitutive inactivation of it should be a relevant example of a pathological variant.
Implementation
The algorithm is implemented in Fortran 95 compiled with GFortran 1 for performance and also in GNU Octave 2 for convenience. The code is available on GitHub 3 at https://github.com/arnaudporet/kali-targ under a BSD 3-Clause License 4 .
Results
This section exposes results produced with the algorithm on the example network.
Results of step 1
Thanks 
Attractors are presented as matrices where, for an attractor of length q, lines correspond to the x i (k), k ∈ [ [1, q] ] and columns to x(k). A physio = {a 1 , a 2 } which corresponds to results obtained by the authors of the example network. By the way, a 1 and a 2 are the two physiological attractors. In term of phenotypes, a 1 corresponds to the accomplishment of a normal cell cycle while a 2 corresponds to quiescence.
Results of steps 2 to 5
Results of steps 2 to 5 are grouped since only therapeutic bullets found in step 4 and classified in step 5 are returned. The algorithm is launched with r min = 1 and r max = 2. Again due to the relatively small size of the example network, max targ and max moda are set to their maximum, namely max targ = 45 and max moda = 4. As a consequence, all the possible bullets with r ∈ [ [1; 2] ] are tested. The algorithm returns the following therapeutic bullets: +CycD silver +CycD −p27 silver −CycD +Rb silver +CycD −Rb silver where + means a therapeutic activation and − a therapeutic inactivation. It should be noted that no golden bullets are found, a not surprising result since they are rarer than silver ones. Given these results, therapeutic activation of Rb alone, which is pathologically inactivated, is not enough to remove pathological attractors. As seen in the third bullet, a therapeutic activation of Rb must be accompanied by a therapeutic inactivation of CycD.
To better illustrate what is performed to obtain therapeutic bullets, below is A patho without any bullet: 
is a physiological attractor. It is possible that the pathological variant produces physiological attractors: A patho is not the set containing exactly all the pathological attractors, it is the attractor set of the pathological variant and it is possible that A physio ∩ A patho = ∅. However, a 3 / ∈ A physio : it is a pathological attractor. In term of phenotypes, a 3 may correspond to a somewhat degenerated cell cycle and is what a therapeutic bullet, being golden or silver, is intended to avoid.
Again to better illustrate what is performed to obtain therapeutic bullets, below is A patho with the third bullet:
which is a 2 . As expected for a therapeutic bullet, the pathological attractor a 3 is removed but the physiological attractor a 1 is not restored: the third bullet is a silver one. Consequently, with this bullet no cell cycle occurs, being normal or degenerated, and the only reachable phenotype is quiescence. While disabling cell cycle of cancer cells is beneficial, what about disabling cell cycle of normal cells. As mentioned above, with silver bullets this is a matter of choice.
Conclusion
Under the assumption stating that dynamical system attractors and biological network phenotypes are linked when the first one models the second one, results show that the algorithm succeeds in performing the proposed in silico target identification. It returns four therapeutic bullets for a pathological variant of the mammalian cell cycle relevant in diseases such as cancer. Consequently, the algorithm can be used on other synchronous boolean models of biological networks involved in disease pathophysiologies for in silico target identification. However, both the physiological and pathological variants have to be known: this can constitute a limit in the application of the proposed methodology. Target identification, being in silico or not, is a step belonging to a wider process: drug discovery. Having an in silico, or even an in vitro, demonstrated potential target is far from having a drug. Further work and many years are necessary before obtaining a drug which is effective in vivo. For example and among other characteristics, such a drug has to be absorbed by the organism, has to reach its target and has to be non toxic at therapeutic dosages. Furthermore, as with any in silico evidence, it should be validated in vitro and ultimately in vivo: there is a bridge to cross between theory and practice. Nevertheless, it is expected that the algorithm is of interest for target identification.
Regarding possible improvements which could be done on the present work, extending the algorithm for asynchronous boolean networks is important since such models are likely to better approach the dynamic of biological systems. Indeed, in biological systems, events can be subjected to stochasticity, do not necessarily occur simultaneously or do not belong to the same time scale, three points that synchronous updating does not take into account. Another possible improvement could be to use finer logics than the boolean one, such as multivalued logics. One of the main limitations of boolean models is that their variables can take only two values. In reality, things are not necessarily binary and variables should be able to take more possible values. Multivalued logics allow it in a discrete manner where variables can take a finite number of values between 0 (false) and 1 (true). For example, one can state that Rb is partly inactivated rather than totally. Such a statement is not implementable with boolean models but is with multivalued ones such as, for example, a three-valued logic where true = 1, moderate = 0.5 and f alse = 0.
Annexes
The algorithm in one block. 
